Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | JUN | P05412 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.73 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 9/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 9/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83322 | 1.00 | RAB9A (0.73) | RAB9AMAPTKDM4ENPC1JUN | |
| SCHEMBL82827 | 0.88 | RAB9A (0.62) | RAB9AMAPTKDM4ENPC1JUN | |
| SCHEMBL5598852 | 0.85 | MAPT (1.00) | RAB9AMAPTKDM4ENPC1JUN | |
| SCHEMBL5598850 | 0.85 | MAPT (1.00) | RAB9AMAPTKDM4ENPC1JUN | |
| Methyl Benzoate SCHEMBL30968567 | 0.83 | ALDH1A1 (0.56) | RAB9AMAPTKDM4ENPC1JUN | |
| SCHEMBL334614 | 0.83 | RAB9A (0.76) | RAB9AMAPTKDM4ENPC1JUN | |
| SCHEMBL29416684 | 0.83 | RAB9A (0.76) | RAB9AMAPTKDM4ENPC1JUN | |
| Hydrochloric Acid SCHEMBL11971079 | 0.83 | MAPT (0.96) | RAB9AMAPTKDM4ENPC1JUN | |
| SCHEMBL334615 | 0.83 | RAB9A (0.76) | RAB9AMAPTKDM4ENPC1JUN | |
| SCHEMBL755249 | 0.83 | RAB9A (0.76) | RAB9AMAPTKDM4ENPC1JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239885-A | Synthesis method of cidamine | 常州合全药业有限公司 | 2024-06-25 | — | — | CN | claimed |
| WO-2024120442-A1 | PAK4 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CONVERGEN (SUZHOU) PHARMACEUTICAL CO., LTD. (CN) | 2024-06-13 | — | — | WO | claimed |
| EP-3856735-B1 | FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-09-06 | — | — | EP | claimed |
| WO-2023030170-A1 | PROTEIN DEGRADATION COMPOUND BASED ON NAMPT TARGET PROTEIN AND APPLICATION THEREOF | 标新生物医药科技(上海)有限公司 | 2023-03-09 | — | — | WO | claimed |
| CN-115703736-A | Multi-target inhibitors targeting HDAC and NAD synthesis and uses thereof | 中国海洋大学 | 2023-02-17 | — | — | CN | claimed |
| WO-2023011416-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | 中国海洋大学 | 2023-02-09 | — | — | WO | claimed |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-28 | — | — | US | claimed |
| EP-3856735-A1 | FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS | New York University (US) | 2021-08-04 | — | — | EP | claimed |
| WO-2020073031-A1 | FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS | NEW YORK UNIVERSITY (US) | 2020-04-09 | — | — | WO | claimed |
| EP-3555078-A1 | BISARYL HETEROCYCLES AS NRF2 ACTI | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | claimed |
| EP-2209765-A2 | HISTONE DEACETYLASE INHIBITORS | Orchid Research Laboratories Limited (IN) | 2010-07-28 | — | — | EP | claimed |
| WO-2009053808-A2 | HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-04-30 | — | — | WO | claimed |
| EP-1594869-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | Targacept, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| JP-2005528361-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1487444-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | Fujisawa Deutschland GmbH (DE) | 2004-12-22 | — | — | EP | claimed |
| WO-2004076449-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| WO-2003080054-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | FUJISAWA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | WO | claimed |
| JP-2002512190-A | — | — | 2002-04-23 | — | — | JP | claimed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | claimed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | NAMPT, NADK, NNT | RAB9A 966/4885MAPT 561/4885KDM4E 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.